Nantes, France

University of Nantes

www.univ-nantes.fr
Nantes, France

The University of Nantes is a French university, located in the city of Nantes. In addition to the several campuses scattered in the city of Nantes, there are two satellite campuses located respectively in Saint-Nazaire and La Roche-sur-Yon. Currently, the University is attended by approximately 34,500 students. More than 10% of them are international students coming from 110 countries.The University of Nantes was ranked between 600-650th in the QS World University Rankings of 2013. On a national scale and regarding the professional insertion after graduation, the University of Nantes oscillates between the ranks 3rd and 40th out of 69 universities depending on the field of studies. On overall, the university is ranked 45th out of 76 universities in France. Among its noticeable alumni are the former French Prime Minister Jean-Marc Ayrault as well as one of the French Ministers of Agriculture. Wikipedia.


Time filter

Source Type

Patent
Hutchinson, French National Center for Scientific Research and University of Nantes | Date: 2016-11-04

The invention relates to an ionogel that may be used for making a self-supporting film forming a solid electrolyte of an electrochemical device, to such a device incorporating this ionogel and to a process for manufacturing this ionogel. The invention generally applies to all energy storage devices such as supercapacitors or storage batteries (e.g. lithium-ion). An ionogel according to the invention comprises: According to the invention, this matrix also comprises a polycondensate of at least one sol-gel molecular precursor bearing hydrolysable group(s).


Patent
Algosource and University of Nantes | Date: 2016-10-17

The method for treating a microalgal biomass, characterized in the following steps: having a microalgal biomass comprising at least 15% by weight of lipids relative to the total weight of the biomass and having a dry matter concentration of between 1 g/l and 200 g/l, milling said biomass by a bead mill, operated under the following conditions: the mean diameter of the beads (d_(GM)) ranges from 0.2 to 2.510^(3 )m, preferably from 0.4 to 1.010^(3 )m and is preferably approximately 0.610^(3 )m, the blade-tip agitation speed () ranges from 4 to 50 ms^(1), preferably from 5 to 20 ms^(1 )and is preferably approximately 8 msec^(1); recovering the composition obtained.


Patent
Blue Solutions, French National Center for Scientific Research and University of Nantes | Date: 2017-01-18

The present invention relates to a positive electrode which includes a composite material, containing sulfur and carbon, as an active material. The invention also relates to the method for manufacturing said electrode, to a lithium-sulfur battery including such a positive electrode, and to the method for manufacturing said battery.


Patent
University of Nantes and French National Center for Scientific Research | Date: 2017-01-18

The invention relates to a method for controlling an automated orbital sander, in which method an electrically powered orbital sander is moved around automatically, at constant pressure, over the surface of an object, along at least one predefined sanding path so as to perform sanding, characterized in that the instantaneous power consumed by the sander along the sanding path is measured and in that the measurement thus taken is processed in order to deduce therefrom information regarding the level of abrasion along said path and/or to detect any sanding incident that has occurred along the latter.


Patent
Institute Pasteur Of Lille, French National Center for Scientific Research and University of Nantes | Date: 2017-04-19

The present invention relates to methods and pharmaceutical compositions for treating pain in subject in need thereof. In particular, the present invention relates to a method of treating pain in a subject thereof comprising administering the subject with at least one agonist of the type 2 angiotensin II receptors (AT2Rs)-TWIK-related arachidonic acid stimulated K+ channel (TRAAK) pathway.


Patent
University of Nantes and French National Center for Scientific Research | Date: 2017-03-29

The present invention relates to methods for determining whether a patient will achieve a response after radiation therapy. In particular, the present invention relates to a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy comprising the steps of i) determining the level of ceramide in a first blood sample obtained from the patient before radiation therapy, ii) determining the level of ceramide in a second blood sample obtained from the patient during or just after radiation therapy, iii) comparing the level determined at step i) with the level determined at step ii) and iv) concluding that the patient will achieve response when the level determined at step ii) is higher than the level determined at step i) or concluding that the patient will not achieve a response when the level determined at step ii) is lower than the level determined at step i).


Patent
University of Nantes | Date: 2017-06-07

The invention relates to an isolated anti-CD45RC antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with CD45RC+ cells. The invention relates to an isolated anti-CD45RC antibody for use in expanding and/or potentiating regulatory T cells.


Patent
University of Nantes | Date: 2017-02-08

The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to isolated peptide of length ranging between 11 and 16 amino acids comprising the amino acid sequence: SDVGEYR (SEQ ID NO: 1) or a function- conservative variant thereof for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8+CD45RClow Tregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8+CD45RClow Tregs is indicative of tolerance.


Patent
Blue Solutions, French National Center for Scientific Research and University of Nantes | Date: 2017-05-24

The invention relates to the field of lithium-sulphur batteries of high energy and power densities. The invention especially relates to a lithium-sulphur battery comprising a biaxially oriented polypropylene porous separator and to the method for the production thereof.


The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.

Loading University of Nantes collaborators
Loading University of Nantes collaborators